TY - JOUR
T1 - Middellangetermijnoverleving na open versus robotgeassisteerde radicale cystectomie in Nederland
T2 - resultaten van de ‘SNAPSHOT’ cystectomie
AU - van Ginkel, Noor
AU - Vis, André N.
AU - Boormans, Joost L.
AU - van der Poel, Henk G.
AU - van der Schoot, Deric K. E.
AU - Aben, Katja K. H.
AU - Hermans, Tom J. N.
AU - Meijer, Dennie
AU - Voortman, Jens
AU - Arends, Tom J. H.
AU - Ausems, Peter J.
AU - Baselmans, Dorine
AU - Berger, Christian P. A. M.
AU - Berrens, Anne-Claire
AU - Bickerstaffe, Henry
AU - Bos, Siebe D.
AU - Braam, Marlene
AU - Buddingh, K. Tim
AU - Claus, Sebastiaan
AU - Dekker, Karen
AU - van Doeveren, Thomas
AU - Einerhand, Sarah M. H.
AU - Fossion, Laurent M. C. Laurent
AU - Hinsenveld, Florentien J.
AU - van Gennep, Erik J.
AU - Grondhuis Palacios, Lorena A.
AU - Hobijn, Mandy M.
AU - van Huystee, Suzanne H.
AU - Jaspers-Valentijn, Martinique
AU - Klaver, O. Sjoerd
AU - Koldewijn, Evert L.
AU - Korsten, Linn
AU - Lenting, Anne
AU - Lentjes, Koen J.
AU - Luiting, Henk B.
AU - van der Meer, Saskia
AU - Mertens, Laura
AU - Nieuwenhuijzen, Jakko A.
AU - Noordzij, M. Arjen
AU - Nooter, Ronald I.
AU - Notenboom, Marije
AU - Oomen, Robert J. A.
AU - van Roermund, Joep G. H.
AU - de Rooij, Judith
AU - Roshani, Hossain
AU - Schrier, Bart P.
AU - van der Slot, Michelle A.
AU - Somford, D. M. Rik
AU - Stelwagen, Piter-Jan
AU - Stroux, Aukje M. A.
AU - van der West, Alwine
AU - Wijsman, Bart P.
AU - Windt, Willemijn A. K. M.
AU - van Zanten, Paul
AU - van Beek, Sytse C.
N1 - Publisher Copyright:
© 2023, The Author(s).
PY - 2023/12
Y1 - 2023/12
N2 - There is insufficient knowledge on intermediate-term survival of non-metastatic muscle-invasive bladder cancer (MIBC) after open (ORC) versus robot-assisted (RARC) cystectomy, with or without neo-adjuvant chemotherapy (NAC). This retrospective study was performed in 19 Dutch hospitals between 2012 and 2015 to assess the five-year survival after both interventions and the influence of NAC. Out of 1,534 cT1-4N0-1-patients, 1,086 patients were treated with ORC and 389 with RARC. The 5‑year survival rate after ORC was 51% (95% CI 47–53) versus 58% after RARC (95% CI 52–63), hazard ratio 1.00 (95% CI 0.84–1.20) after multivariable analysis. 226 of 965 cT2-4aN0 patients were treated with NAC. More patients had ypT0 after NAC than after no NAC (31% vs 15%; p < 0.01). The best five-year survival was in patients with ypT0 after NAC (89%; 95% CI 81–97). This study shows similar five-year survival of MIBC patients treated with ORC or RARC and shows that the best survival was after NAC.
AB - There is insufficient knowledge on intermediate-term survival of non-metastatic muscle-invasive bladder cancer (MIBC) after open (ORC) versus robot-assisted (RARC) cystectomy, with or without neo-adjuvant chemotherapy (NAC). This retrospective study was performed in 19 Dutch hospitals between 2012 and 2015 to assess the five-year survival after both interventions and the influence of NAC. Out of 1,534 cT1-4N0-1-patients, 1,086 patients were treated with ORC and 389 with RARC. The 5‑year survival rate after ORC was 51% (95% CI 47–53) versus 58% after RARC (95% CI 52–63), hazard ratio 1.00 (95% CI 0.84–1.20) after multivariable analysis. 226 of 965 cT2-4aN0 patients were treated with NAC. More patients had ypT0 after NAC than after no NAC (31% vs 15%; p < 0.01). The best five-year survival was in patients with ypT0 after NAC (89%; 95% CI 81–97). This study shows similar five-year survival of MIBC patients treated with ORC or RARC and shows that the best survival was after NAC.
KW - chemotherapy
KW - muscle-invasive bladdercancer
KW - prognosis
KW - radical cystectomy
UR - https://www.scopus.com/pages/publications/85176406111
U2 - 10.1007/s13629-023-00409-x
DO - 10.1007/s13629-023-00409-x
M3 - Article
SN - 2211-3037
VL - 13
SP - 164
EP - 175
JO - Tijdschrift voor urologie
JF - Tijdschrift voor urologie
IS - 8
ER -
SDG 3 Good Health and Well-being